Blood

Vol. 146, Issue Supplement 1 Issue Supplement 1 2025
8248
Articles

Articles in this Issue

primary prophylaxis with direct oral anticoagulants (DOACs) for transwomen taking estrogen is not cost-effective

Jorge Ruiz Lopez, Sarah Peterson, Satoko Ito et al. Nov 03, 2025 pp. 6161-6161 10.1182/blood-2025-6161

Abstract Introduction: Gender affirming hormonal therapy (GAHT), particularly estrogen-based regimens, is a vital part of gender-affirming c...

Simultaneous PD-1 and VIP receptor blockade optimizes tumor immunotherapy in P815 Acute Myeloid Leukemia model

Stella Lee, Jian-Ming Li, Edmund Waller Nov 03, 2025 pp. 2546-2546 10.1182/blood-2025-2546

Abstract Anti-programmed death-1 (PD-1) therapy enhances anti-tumor immunity in many solid tumors, but is largely ineffective in acute myelo...

Association of social determinants of health (SDoH) with clinic visit adherence, healthcare utilization and hydroxyurea (HU) acceptance and adherence in children with sickle cell disease (SCD)

Melinda Chance, Elizabeth Baker, Gabriela Oates et al. Nov 03, 2025 pp. 4438-4438 10.1182/blood-2025-4438

Abstract Background: Children with chronic diseases living in deprived neighborhoods have lower medication adherence and poorer health outco...

A novel protocol of dual passing cord blood pre-/post-transplant reduced relapse in TCRαβ cell depleted HCT

Huaying Liu, Zhiyong Peng, Yuanying Zeng et al. Nov 03, 2025 pp. 6062-6062 10.1182/blood-2025-6062

Abstract Background How to overcome post-transplant relapse (PTR) is the main challenge in current. PTR is 20% or higher in haplo-HCT. An ad...

Unexplained bleeding and a hidden inhibitor: A case of late-onset acquired hemophilia A

Sumit Sharma, Priyanka Sharma, Ecem Kalemoglu et al. Nov 03, 2025 pp. 6633-6633 10.1182/blood-2025-6633

Abstract Background: Acquired hemophilia A (AHA) is a rare autoimmune bleeding disorder caused by autoantibodies against...

Phase II Trial of lenalidomide plus rituximab (R2) in previously untreated follicular lymphoma: 15-year follow up data from MDACC Trial

Dai Chihara, Paolo Strati, Preetesh Jain et al. Nov 03, 2025 pp. 5369-5369 10.1182/blood-2025-5369

Abstract Introduction: Lenalidomide with rituximab (R2) as first line treatment for patients with previously untreated follicular lymphoma (...

Risk factors for disseminated intravascular coagulation in pediatric acute promyelocytic leukemia: Insights from the cclg-APL 2016 study

Qingyuan Xu, Linya Wang, Yaguang Peng et al. Nov 03, 2025 pp. 1599-1599 10.1182/blood-2025-1599

Abstract Purpose: To identify early risk factors for DIC, particularly severe DIC (grade 4-5), in pediatric APL, with the aim of guiding ear...

Charlotte African American MGUS project (CHAAMP): A prospective pilot study of MGUS screening in black and/or African American adults

Manisha Bhutani, Myra Robinson, Margarita Dzhanumova et al. Nov 03, 2025 pp. 8244-8244 10.1182/blood-2025-8244

Abstract Background Among Black and/or African American individuals, multiple myeloma (MM) is the most common hematologic malignancy, occurr...

Post-traumatic stress disorder in patients with multiple myeloma (MM) and non-Hodgkin lymphoma (NHL)

Yagnapriya Ammakola, Ankith Motkar, Shashank Cingam Nov 03, 2025 pp. 2776-2776 10.1182/blood-2025-2776

Abstract Background Multiple Myeloma (MM) and non-Hodgkin lymphoma (NHL) are hematologic malignancies contributing...

Clinical and experimental characteristics of a hereditary thrombocythemia family with co-mutation in JAK2 involving ferm and pseudo-kinase domains

Qiguo Zhang, Yuyan Zhang, Wenjing Fu et al. Nov 03, 2025 pp. 7326-7326 10.1182/blood-2025-7326

Abstract Objective: To enhance understanding of familial hereditary thrombocythemia (HT) associated with novel JAK2 germline mutations and i...

Risk stratification based on machine learning for severe cytokine release syndrome in RRMM patients treated with bispecific antibodies

Roberto Mancebo-Martin, Magdalena Corona De Lapuerta, Lara Rodriguez-Luque et al. Nov 03, 2025 pp. 6349-6349 10.1182/blood-2025-6349

Abstract Introduction T-cell redirecting bispecific antibodies (BsAbs) have significantly advanced treatment of relapsed/refractory multiple...

Impact of allogeneic transplant vs hypomethylating agents in high-risk myelodysplastic syndromes: A prisma-guided systematic review

Kalan Patel, Janamejey Gaur, Alina Bhat Nov 03, 2025 pp. 7369-7369 10.1182/blood-2025-7369

Abstract Background High-risk myelodysplastic syndromes (MDS)—those falling into IPSS Int-2/High or IPSS-R High/Very-High categories—still c...

Umbilical cord blood CD34+ hematopoietic stem cell-derived natural killer cells in Acute Myeloid Leukemia – a phase I clinical study

Michael Heuser, Anna-Maria Georgoudaki, Adrian Schwarzer et al. Nov 03, 2025 pp. 1640-1640 10.1182/blood-2025-1640

Abstract Background: The use of fresh umbilical cord blood (UCB) CD34+ hematopoietic stem cell (HSC)-derived allogeneic natural killer (NK)...

TP53 mutational spectrum and fitness landscape in myeloid neoplasia

Ersan Unlu, Waled Bahaj, Tariq Kewan et al. Nov 03, 2025 pp. 4360-4360 10.1182/blood-2025-4360

Abstract Myeloid neoplasia encompasses a heterogeneous and complex molecular landscape whereby the distinct combinatorial patterns associate...

Transduction efficiency and vector biodistribution following prenatal vs neonatal AAV5 gene therapy for Hemophilia A in a sheep model

Martin Rodriguez, Walaa Mohamed, Oluwaseun Babatunde et al. Nov 03, 2025 pp. 4316-4316 10.1182/blood-2025-4316

Abstract Hemophilia A (HA) patients treated with AAV-based gene therapy (GT) receive vector serotypes that preclinical studies indicated to...

Differences in patient-reported time toxicity between bispecific antibody (BsAb) options: Impact of treatment duration and dosing frequency on patient-reported time burden in relapsed/refractory (R/R) follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL)

Ajay Major, Esprit Ma, Anthony Masaquel et al. Nov 03, 2025 pp. 6181-6181 10.1182/blood-2025-6181

Abstract Background Several BsAbs with different treatment (Tx) approaches have been approved by the FDA for Tx of lymphoma, including: fixe...

Odronextamab treatment for patients with rare subtypes of relapsed/refractory (R/R) aggressive B-cell non-Hodgkin lymphoma (B-NHL): Updated efficacy and safety analyses from a dedicated cohort of the ELM-2 study

Mary-Margaret Keating, Tae Min Kim, Farrukh Awan et al. Nov 03, 2025 pp. 5523-5523 10.1182/blood-2025-5523

Abstract Introduction Aggressive B-NHL includes rare subtypes such as transformed diffuse large B-cell lymphoma (t-DLBCL...

A US real-world analysis of demographics, transplant patterns, and survival outcomes in posttransplant lymphoproliferative disorder (PTLD)

Heidi Latiolais, Michael Halpern, Zohra Nooruddin et al. Nov 03, 2025 pp. 5442-5442 10.1182/blood-2025-5442

Abstract Introduction: Posttransplant lymphoproliferative disorder (PTLD) is a rare but serious complication that can occur following solid...

T cell resistance to glucocorticoids in graft-versus-host disease

Andrew McIntyre, Lisanne Schoutens, Elisa Armbrecht et al. Nov 03, 2025 pp. 2316-2316 10.1182/blood-2025-2316

Abstract Glucocorticoid (GC)-resistant, acute graft-versus-host-disease (GVHD) is a major cause of mortality following allogeneic hematopoie...

Incidence of arterial thromboembolism in patients with myeloproliferative neoplasms treated with anticoagulation for venous thromboembolism

Antonia Chan, Rodyna Mostafa, Sangam Sangam et al. Nov 03, 2025 pp. 3138-3138 10.1182/blood-2025-3138

Abstract Background Patients with myeloproliferative neoplasms (MPN) have a high lifetime risk of both venous thromboembolism (VTE) and arter...

The efficacy of immunotherapy in alveolar soft part sarcoma (ASPS): A case report

Jennie Reisman, Jason White Nov 03, 2025 pp. 7655-7655 10.1182/blood-2025-7655

Abstract Introduction: Alveolar Soft Part Sarcoma (ASPS) is an extremely rare sarcoma, accounting for 1% of soft tissue tumors that predomin...

Liquid biopsy for non-invasive molecular characterization and measurable residual disease analysis in multiple myeloma

Jan Vorwerk, Anke Schilhabel, Philipp Nakov et al. Nov 03, 2025 pp. 2208-2208 10.1182/blood-2025-2208

Abstract Introduction: Molecular profiling and measurable residual disease (MRD) assessment have become essential in multiple myeloma (MM) d...

Xeroderma pigmentosum as a germline predisposition syndrome for haematological malignancies

Manar Alfaham, Yousef Binamer, Ghulam Mufti et al. Nov 03, 2025 pp. 6749-6749 10.1182/blood-2025-6749

Abstract IntroductionXeroderma pigmentosum (XP) is a rare autosomal recessive disorder caused by defects in the nucleotide excision repair p...

Pomalidomide promotes activation induced cell death of pre-activated, memory BCMA CAR-T cells in a model of high, but not low, tumor burden multiple myeloma

Kirsten Pfeffer, Yuan Zhu, Chang-Xin Shi et al. Nov 03, 2025 pp. 5728-5728 10.1182/blood-2025-5728

Abstract Introduction High disease burden has been associated with reduced efficacy and resistance to BCMA CAR-T therapy in relapsed/refract...

Bone marrow environmental alterations underlie proliferative clonal expansion in clonal hematopoiesis

Masahiro Nakagawa, Ryosaku Inagaki, Yasuhito Nannya et al. Nov 03, 2025 pp. 632-632 10.1182/blood-2025-632

Abstract Background Age-related clonal hematopoiesis (CH) is common in the elderly and associated with increased risk of hematologic maligna...

All Issues

Journal Info

Publisher Elsevier BV
ISSN 0006-4971
E-ISSN 1528-0020
Subject Health Sciences
Language English
View Full Journal Page